EPO and bronchopulmonary dysplasia: While retrospective studies have suggested a potential benefit of erythropoietin in reducing BPD in preterm infants, a meta-analysis of 17 RCTs found no difference in the incidence of BPD between infants receiving EPO and those receiving placebo (179–181).